文献速递腹部泌尿生殖MR

非增强简化MRI检测MRI肝脏影像报告和数据系统LR-3及LR-4观察中肝细胞癌的研究

Non-contrast abbreviated MRI for the detection of hepatocellular carcinoma in patients with Liver Imaging Reporting and Data System LR-3 and LR-4 observations in MRI.
PubMed 文献 · Br J Radiol · 2024-01-01

这项前瞻性研究纳入63例肝硬化患者,在肝细胞癌监测中经增强MRI发现LI-RADS LR-3和LR-4观察,共166次增强MRI随访,12例发展为肝细胞癌(平均大小19.6 mm)。非增强简化MRI(DWI+T2WI+T1WI)敏感度91.7%(95%CI 61.5-99.8)、特异度91.6%(95%CI 86.0-95.4)、AUC 0.92(95%CI 0.83-1.00)。

要点

  • 非增强简化MRI(DWI+T2WI+T1WI)检测肝细胞癌敏感度91.7%、特异度91.6%、AUC 0.92。
  • ALBI 1级与2级特异度86.7% vs 98.4%(P=.010),病毒性与非病毒性肝硬化特异度93.8% vs 80.8%(P=.010)。
  • 在不同BMI、病灶大小、Child-Turcotte-Pugh分级及MELD分级间敏感度保持一致。

核心结论

  • 非增强简化MRI在临床可行,在检测肝细胞癌方面表现出高诊断性能。

研究设计与样本

  • 前瞻性研究,纳入63例肝硬化患者、共166次增强MRI随访;患者平均接受3轮完整增强MRI(间隔3-6个月),随访约12个月;非增强简化MRI包括DWI、T2WI和T1WI,由2名经验丰富的放射科医生独立阅片,以Kappa系数评估阅片者间一致性;参考标准为美国肝病研究学会定义的增强MRI门静脉期或延迟期动脉期高强化伴廓清。

诊断标准与关键数值

  • 非增强简化MRI(DWI+T2WI+T1WI)检测肝细胞癌:敏感度91.7%(95%CI 61.5-99.8),特异度91.6%(95%CI 86.0-95.4),AUC 0.92(95%CI 0.83-1.00);ALBI 1级特异度86.7% vs ALBI 2级98.4%(P=.010);病毒性肝硬化特异度93.8% vs 非病毒性肝硬化80.8%(P=.010)。

临床应用与阅片要点

  • 在肝硬化患者增强MRI监测发现LI-RADS LR-3和LR-4观察时,非增强简化MRI(DWI+T2WI+T1WI)可用于检测肝细胞癌;不同BMI、病灶大小、Child-Turcotte-Pugh分级、ALBI分级和MELD分级间敏感度保持一致,但ALBI 1级与2级间、病毒性与非病毒性肝硬化间特异度存在显著差异。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND AND AIMS: With ultrasound sensitivity limited in hepatocellular carcinoma (HCC) surveillance and few prospective studies on non-contrast abbreviated MRI (NC-AMRI), this study aimed to assess its diagnostic performance in detecting HCC.

METHODS: This prospective study involved cirrhotic patients with contrast-enhanced MRI (CE-MRI) Liver Imaging Reporting and Data System (LI-RADS) LR-3 and LR-4 observations detected during HCC surveillance. Patients underwent average 3 complete CE-MRI rounds at 3-6 months interval, with approximately 12-month follow-up. NC-AMRI included diffusion-weighted (DWI), T2-weighted imaging (T2WI), and T1-weighted imaging (T1WI). NC-AMRI protocol images were analysed for diagnostic performance, with subgroup analyses. CE-MRI and NC-AMRI images were independently reviewed by 2 experienced radiologists, with inter-reader agreement assessed with Kappa coefficient. The reference standard was the American Association for the Study of Liver Diseases-defined presence of arterial hypervascularity and washout during the portal-venous or delayed phases on CE-MRI.

RESULTS: In 166 CE-MRI follow-ups of 63 patients (median age: 63 years; 60.3% male, 39.7% female), 12 patients developed HCC, with average size of 19.6 mm. The NC-AMRI (DWI + T2WI + T1WI) showed 91.7% sensitivity (95%CI, 61.5-99.8) and 91.6% specificity (95%CI, 86.0-95.4), area under receiver operating characteristic 0.92 (95%CI, 0.83-1.00). Across different Body Mass Index categories, lesion size, Child-Turcotte-Pugh classes, Albumin-Bilirubin (ALBI) grades, and Model for End-Stage Liver Disease classes, sensitivity remained consistent. However, specificity differed significantly between ALBI grade 1 and 2 (86.7% vs. 98.4%, P = .010), and between viral and non-viral cirrhosis (93.8% vs. 80.8%, P = .010).

CONCLUSIONS: NC-AMRI proved clinically feasible, and exhibits high diagnostic performance in HCC detection.

ADVANCES IN KNOWLEDGE: This study highlights efficacy of NC-AMRI in detecting HCC among cirrhotic patients with LR-3 and LR-4 observations, representing significant progress in HCC surveillance.

来源:Br J Radiol,查看原文。版权归原作者所有。

引用

  1. Maung ST, Tanpowpong N, Satja M, et al. Non-contrast abbreviated MRI for the detection of hepatocellular carcinoma in patients with Liver Imaging Reporting and Data System LR-3 and LR-4 observations in MRI. Br J Radiol. 2024. PMID: 39115388. doi:10.1093/bjr/tqae140

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。